Contemporary evidence on colorectal liver metastases ablation: toward a paradigm shift in locoregional treatment

References

• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Colon Cancer (Version 2.2021) 2021. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428.
   Google Scholar
• Di Martino M, Rompianesi G, Mora-Guzmán I, et al. Systematic review and meta-analysis of local ablative therapies for resectable colorectal liver metastases. Eur J Surg Oncol. 2020;46(5):772–781.
   PubMed Web of Science ®Google Scholar
• Otto G, Düber C, Hoppe-Lotichius M, et al. Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Ann Surg. 2010;251(5):796–803.
   PubMed Web of Science ®Google Scholar
• Nishiwada S, Ko S, Mukogawa T, et al. Comparison between percutaneous radiofrequency ablation and surgical hepatectomy focusing on local disease control rate for colorectal liver metastases. Hepatogastroenterology. 2014;61(130):436–441.
   PubMedGoogle Scholar
• Berber E, Tsinberg M, Tellioglu G, et al. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg. 2008;12(11):1967–1972.
   PubMed Web of Science ®Google Scholar
• McKay A, Fradette K, Lipschitz J. Long-term outcomes following hepatic resection and radiofrequency ablation of colorectal liver metastases. HPB Surg. 2009; 2009:346863.
   PubMedGoogle Scholar
• Kron P, Linecker M, Jones RP, et al. Ablation or resection for colorectal liver metastases? A systematic review of the literature. Front Oncol. 2019;9:1052.
   PubMed Web of Science ®Google Scholar
• Lee WS, Yun SH, Chun HK, et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J Clin Gastroenterol. 2008;42(8):945–949.
   PubMed Web of Science ®Google Scholar
• Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–766.
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241(5):715–722.
   PubMed Web of Science ®Google Scholar
• Margonis GA, Sergentanis TN, Ntanasis-Stathopoulos I, et al. Impact of surgical margin width on recurrence and overall survival following R0 hepatic resection of colorectal metastases: a systematic review and meta-analysis. Ann Surg. 2018;267(6):1047–1055.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Solbiati L, Brace CL, Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria-a 10-year update. J Vasc Interv Radiol. 2014;25(11):1691–1705.e4.
   PubMed Web of Science ®Google Scholar
• Hamada A, Yamakado K, Nakatsuka A, et al. Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates. Jpn J Radiol. 2012;30(7):567–574.
   PubMed Web of Science ®Google Scholar
• Shady W, Petre EN, Gonen M, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes–a 10-year experience at a single center. Radiology. 2016;278(2):601–611.
   PubMed Web of Science ®Google Scholar
• Gillams A, Goldberg N, Ahmed M, et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology sans frontières meeting 2013. Eur Radiol. 2015;25(12):3438–3454.
   PubMed Web of Science ®Google Scholar
• Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol. 2009;19(5):1206–1213.
   PubMed Web of Science ®Google Scholar
• Petre EN, Jia X, Thornton RH, et al. Treatment of pulmonary colorectal metastases by radiofrequency ablation. Clin Colorectal Cancer. 2013;12(1):37–44.
   PubMed Web of Science ®Google Scholar
• Nieuwenhuizen S, Puijk RS, van den Bemd B, et al. Resectability and ablatability criteria for the treatment of liver only colorectal metastases: multidisciplinary consensus document from the COLLISION trial group. Cancers (Basel). 2020;12(7):1779.
   PubMed Web of Science ®Google Scholar
• Siperstein AE, Berber E, Ballem N, et al. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 2007;246(4):559–565.
   PubMed Web of Science ®Google Scholar
• Wang CZ, Yan GX, Xin H, Liu ZY. Oncological outcomes and predictors of radiofrequency ablation of colorectal cancer liver metastases. World J Gastrointest Oncol. 2020;12(9):1044–1055.
   PubMed Web of Science ®Google Scholar
• Han K, Kim JH, Yang SG, et al. A single-center retrospective analysis of periprocedural variables affecting local tumor progression after radiofrequency ablation of colorectal cancer liver metastases. Radiology. 2021;298(1):212–218.
   PubMed Web of Science ®Google Scholar
• Shi Y, Wang Z, Chi J, et al. Long-term results of percutaneous microwave ablation for colorectal liver metastases. HPB (Oxford)). 2021;23(1):37–45.
   PubMed Web of Science ®Google Scholar
• Wang X, Sofocleous CT, Erinjeri JP, et al. Margin size is an independent predictor of local tumor progression after ablation of Colon cancer liver metastases. Cardiovasc Intervent Radiol. 2013;36(1):166–175.
   PubMed Web of Science ®Google Scholar
• Qin S, Liu GJ, Huang M, et al. The local efficacy and influencing factors of ultrasound-guided percutaneous microwave ablation in colorectal liver metastases: a review of a 4-year experience at a single center. Int J Hyperthermia. 2019;36(1):36–43.
   PubMed Web of Science ®Google Scholar
• Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol. 2005;23(7):1358–1364.
   PubMed Web of Science ®Google Scholar
• Mulier S, Ni Y, Jamart J, et al. Local recurrence after hepatic radiofrequency coagulation: multivariate Meta-analysis and review of contributing factors. Ann Surg. 2005;242(2):158–171.
   PubMed Web of Science ®Google Scholar
• Ayav A, Germain A, Marchal F, et al. Radiofrequency ablation of unresectable liver tumors: factors associated with incomplete ablation or local recurrence. Am J Surg. 2010;200(4):435–439.
   PubMed Web of Science ®Google Scholar
• Tanis E, Nordlinger B, Mauer M, et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European organisation for research and treatment of cancer #40004 and #40983. Eur J Cancer. 2014;50(5):912–919.
   PubMed Web of Science ®Google Scholar
• Yu NC, Raman SS, Kim YJ, et al. Microwave liver ablation: influence of hepatic vein size on heat-sink effect in a porcine model. J Vasc Interv Radiol. 2008;19(7):1087–1092.
   PubMed Web of Science ®Google Scholar
• Pillai K, Akhter J, Chua TC, et al. Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model. Medicine (Baltimore)). 2015;94(9):e580.
   PubMed Web of Science ®Google Scholar
• Rhaiem R, Kianmanesh R, Minon M, et al. Microwave thermoablation of colorectal liver metastases close to large hepatic vessels under pringle maneuver minimizes the "Heat Sink Effect”. World J Surg. 2020;44(5):1595–1603.
   PubMed Web of Science ®Google Scholar
• Bhardwaj N, Dormer J, Ahmad F, et al. Microwave ablation of the liver: a description of lesion evolution over time and an investigation of the heat sink effect. Pathology. 2011;43(7):725–731.
   PubMed Web of Science ®Google Scholar
• Ringe KI, Lutat C, Rieder C, et al. Experimental evaluation of the heat sink effect in hepatic microwave ablation. PLoS One. 2015;10(7):e0134301.
   PubMed Web of Science ®Google Scholar
• van Tilborg AA, Scheffer HJ, de Jong MC, et al. MWA versus RFA for perivascular and peribiliary CRLM: a retrospective patient- and lesion-Based analysis of two historical cohorts. Cardiovasc Intervent Radiol. 2016;39(10):1438–1446.
   PubMed Web of Science ®Google Scholar
• Marchal F, Elias D, Rauch P, et al. Biliary lesions during radiofrequency ablation in liver. Study on the pig. Eur Surg Res. 2004;36(2):88–94.
   PubMed Web of Science ®Google Scholar
• Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226(2):441–451.
   PubMed Web of Science ®Google Scholar
• Liang P, Wang Y, Yu X, et al. Malignant liver tumors: treatment with percutaneous microwave ablation–complications among cohort of 1136 patients. Radiology. 2009;251(3):933–940.
   PubMed Web of Science ®Google Scholar
• Silk MT, Wimmer T, Lee KS, et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Interv Radiol. 2014;25(1):112–118.
   PubMed Web of Science ®Google Scholar
• Dollinger M, Zeman F, Niessen C, et al. Bile duct injury after irreversible electroporation of hepatic malignancies: evaluation of MR imaging findings and laboratory values. J Vasc Interv Radiol. 2016;27(1):96–103.
   PubMed Web of Science ®Google Scholar
• Lee EW, Wong D, Prikhodko SV, et al. Electron microscopic demonstration and evaluation of irreversible electroporation-induced nanopores on hepatocyte membranes. J Vasc Interv Radiol. 2012;23(1):107–113.
   PubMed Web of Science ®Google Scholar
• Liu C, He J, Li T, et al. Evaluation of the efficacy and postoperative outcomes of hydrodissection-assisted microwave ablation for subcapsular hepatocellular carcinoma and colorectal liver metastases. Abdom Radiol (NY). 2021;46(5):2161–2172.
   Web of Science ®Google Scholar
• Sartori S, Tombesi P, Macario F, et al. Subcapsular liver tumors treated with percutaneous radiofrequency ablation: a prospective comparison with nonsubcapsular liver tumors for safety and effectiveness. Radiology. 2008;248(2):670–679.
   PubMed Web of Science ®Google Scholar
• Shady W, Petre EN, Do KG, et al. Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: Ablation with clear margins (A0) provides the best local tumor control. J Vasc Interv Radiol. 2018;29(2):268–275.e1.
   PubMed Web of Science ®Google Scholar
• Odisio BC, Yamashita S, Huang SY, et al. Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg. 2017;104(6):760–768.
   PubMed Web of Science ®Google Scholar
• Calandri M, Yamashita S, Gazzera C, et al. Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. Eur Radiol. 2018;28(7):2727–2734.
   PubMed Web of Science ®Google Scholar
• Shady W, Petre EN, Vakiani E, et al. Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget. 2017;8(39):66117–66127.
   PubMedGoogle Scholar
• Jiang BB, Yan K, Zhang ZY, et al. The value of KRAS gene status in predicting local tumor progression of colorectal liver metastases following radiofrequency ablation. Int J Hyperthermia. 2019;36(1):211–219.
   PubMed Web of Science ®Google Scholar
• Lin YM, Taiji R, Calandri M, et al. Tumor biomarkers and interventional oncology: Impact on local outcomes for liver and lung malignancy. Curr Oncol Rep. 2021;23(6):67.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lenz HJ, Kohne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33(7):692–700.
   PubMed Web of Science ®Google Scholar
• Zimmitti G, Shindoh J, Mise Y, et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol. 2015;22(3):834–842.
   PubMed Web of Science ®Google Scholar
• Schramm K, Krause K, Bittroff-Leben A, et al. D. Activated K-ras is involved in regulation of integrin expression in human Colon carcinoma cells. Int J Cancer. 2000;87(2):155–164.
   PubMed Web of Science ®Google Scholar
• Brudvik KW, Mise Y, Chung MH, et al. RAS mutation predicts positive resection margins and narrower resection margins in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol. 2016;23(8):2635–2643.
   PubMed Web of Science ®Google Scholar
• Veltri A, Sacchetto P, Tosetti I, et al. Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. Cardiovasc Intervent Radiol. 2008;31(5):948–956.
   PubMed Web of Science ®Google Scholar
• van Duijnhoven FH, Jansen MC, Junggeburt JM, et al. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol. 2006;13(5):651–658.
   PubMed Web of Science ®Google Scholar
• Puijk RS, Nieuwenhuizen S, van den Bemd BAT, et al. Transcatheter CT hepatic arteriography compared with conventional CT fluoroscopy guidance in percutaneous thermal ablation to treat colorectal liver metastases: a single-center comparative analysis of 2 historical cohorts. J Vasc Interv Radiol. 2020;31(11):1772–1783.
   PubMed Web of Science ®Google Scholar
• Lin Gc EY, Brock KB, Avritscher R, et al. Intra-arterial CT hepatic angiography for tumor detection and ablation endpoint assessment: a proof-of-concept analysis. Cardiovasc Intervent Radiol. 2019;42(3):65–549.
   PubMedGoogle Scholar
• Mauri G, Cova L, De Beni S, et al. Real-time US-CT/MRI image fusion for guidance of thermal ablation of liver tumors undetectable with US: results in 295 cases. Cardiovasc Intervent Radiol. 2015;38(1):143–151.
   PubMed Web of Science ®Google Scholar
• Schullian P, Johnston E, Laimer G, et al. Thermal ablation of CT 'invisible' liver tumors using MRI fusion: a case control study. Int J Hyperthermia. 2020;37(1):564–572.
   PubMed Web of Science ®Google Scholar
• Moulton CA, Gu CS, Law CH, et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. Jama. 2014;311(18):1863–1869.
   PubMed Web of Science ®Google Scholar
• Oba A, Mise Y, Ito H, et al. Clinical implications of disappearing colorectal liver metastases have changed in the era of hepatocyte-specific MRI and contrast-enhanced intraoperative ultrasonography. HPB (Oxford)). 2018;20(8):708–714.
   PubMed Web of Science ®Google Scholar
• Kurilova I, Bendet A, Petre EN, et al. Factors associated with local tumor control and complications after thermal ablation of colorectal cancer liver metastases: a 15-year retrospective cohort study. Clin Colorectal Cancer. 2021;20(2):e82–e95.
   Web of Science ®Google Scholar
• Yu J, Liang P, Yu X, et al. A comparison of microwave ablation and bipolar radiofrequency ablation both with an internally cooled probe: results in ex vivo and in vivo porcine livers. Eur J Radiol. 2011;79(1):124–130.
   PubMed Web of Science ®Google Scholar
• Berber E. The first clinical application of planning software for laparoscopic microwave thermosphere ablation of malignant liver tumours. HPB (Oxford)). 2015;17(7):632–636.
   PubMed Web of Science ®Google Scholar
• Bale R, Widmann G, Stoffner DI. Stereotaxy: breaking the limits of current radiofrequency ablation techniques. Eur J Radiol. 2010;75(1):32–6.
   PubMed Web of Science ®Google Scholar
• Bale R, Widmann G, Schullian P, et al. Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases. Eur Radiol. 2012;22(4):930–937.
   PubMed Web of Science ®Google Scholar
• Agcaoglu O, Aliyev S, Karabulut K, et al. Complementary use of resection and radiofrequency ablation for the treatment of colorectal liver metastases: an analysis of 395 patients. World J Surg. 2013;37(6):1333–1339.
   PubMed Web of Science ®Google Scholar
• Hammill CW, Billingsley KG, Cassera MA, et al. Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases. Ann Surg Oncol. 2011;18(7):1947–1954.
   PubMed Web of Science ®Google Scholar
• Reuter NP, Woodall CE, Scoggins CR, et al. Ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J Gastrointest Surg. 2009;13(3):486–491.
   PubMed Web of Science ®Google Scholar
• Nielsen K, van Tilborg AA, Meijerink MR, et al. Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg. 2013;37(6):1340–1347.
   PubMed Web of Science ®Google Scholar
• Sofocleous CT, Petre EN, Gonen M, et al. CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy. J Vasc Interv Radiol. 2011;22(6):755–761.
   PubMed Web of Science ®Google Scholar
• Jakobs TF, Hoffmann RT, Trumm C, et al. Radiofrequency ablation of colorectal liver metastases: mid-term results in 68 patients. Anticancer Res. 2006;26(1b):671–680.
   PubMed Web of Science ®Google Scholar
• Wong J, Lee KF, Yu SC, et al. Percutaneous radiofrequency ablation versus surgical radiofrequency ablation for malignant liver tumours: the long-term results. HPB (Oxford)). 2013;15(8):595–601.
   PubMed Web of Science ®Google Scholar
• van Amerongen MJ, Jenniskens SFM, van den Boezem PB, Fütterer JJ, et al. Radiofrequency ablation compared to surgical resection for curative treatment of patients with colorectal liver metastases - a Meta-analysis. HPB (Oxford)). 2017;19(9):749–756.
   PubMed Web of Science ®Google Scholar
• Piccioni F, Poli A, Templeton LC, et al. Anesthesia for percutaneous radiofrequency tumor ablation (PRFA): a review of current practice and techniques. Local Reg Anesth. 2019;12:127–137.
   PubMed Web of Science ®Google Scholar
• Denys A, Lachenal Y, Duran R, et al. Use of high-frequency jet ventilation for percutaneous tumor ablation. Cardiovasc Intervent Radiol. 2014;37(1):140–146.
   PubMed Web of Science ®Google Scholar
• Puijk RS, Ziedses Des Plantes V, Nieuwenhuizen S, et al. Propofol compared to midazolam sedation and to general anesthesia for percutaneous microwave ablation in patients with hepatic malignancies: a Single-Center comparative analysis of three historical cohorts. Cardiovasc Intervent Radiol. 2019;42(11):1597–1608.
   PubMed Web of Science ®Google Scholar
• Muratore A, Ribero D, Zimmitti G, et al. Resection margin and recurrence-free survival after liver resection of colorectal metastases. Ann Surg Oncol. 2010;17(5):1324–1329.
   PubMed Web of Science ®Google Scholar
• Izaaryene J, Drai M, Deniel C, et al. Computed tomography-guided microwave ablation of perivascular liver metastases from colorectal cancer: a study of the ablation zone, feasibility, and safety. Int J Hyperthermia. 2021;38(1):887–899.
   PubMed Web of Science ®Google Scholar
• Laimer G, Schullian P, Putzer D, et al. Can accurate evaluation of the treatment success after radiofrequency ablation of liver tumors be achieved by visual inspection alone? Results of a blinded assessment with 38 interventional oncologists. Int J Hyperthermia. 2020;37(1):1362–1367.
   PubMed Web of Science ®Google Scholar
• Laimer G, Schullian P, Jaschke N, et al. Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation. Eur Radiol. 2020;30(5):2463–2472.
   PubMed Web of Science ®Google Scholar
• Kaye EA, Cornelis FH, Petre EN, et al. Volumetric 3D assessment of ablation zones after thermal ablation of colorectal liver metastases to improve prediction of local tumor progression. Eur Radiol. 2019;29(5):2698–2705.
   PubMed Web of Science ®Google Scholar
• Kim YS, Lee WJ, Rhim H, et al. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol. 2010;195(3):758–765.
   PubMed Web of Science ®Google Scholar
• Sibinga Mulder BG, Hendriks P, Baetens TR, et al. Quantitative margin assessment of radiofrequency ablation of a solitary colorectal hepatic metastasis using MIRADA RTx on CT scans: a feasibility study. BMC Med Imaging. 2019;19(1):71.
   PubMed Web of Science ®Google Scholar
• Bo XW, Xu HX, Guo LH, et al. Ablative safety margin depicted by fusion imaging with post-treatment contrast-enhanced ultrasound and pre-treatment CECT/CEMRI after radiofrequency ablation for liver cancers. BJR. 2017;90(1078):20170063.
   Google Scholar
• Shyn PB, Casadaban LC, Sainani NI, et al. Intraprocedural ablation margin assessment by using ammonia perfusion PET during FDG PET/CT-guided liver tumor ablation: a pilot study. Radiology. 2018;288(1):138–145.
   PubMed Web of Science ®Google Scholar
• Ryan ER, Sofocleous CT, Schöder H, et al. Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology. 2013;268(1):288–295.
   PubMed Web of Science ®Google Scholar
• Cornelis FH, Petre EN, Vakiani E, et al. Immediate postablation 18F-FDG injection and corresponding SUV are surrogate biomarkers of local tumor progression after thermal ablation of colorectal carcinoma liver metastases. J Nucl Med. 2018;59(9):1360–1365.
   PubMed Web of Science ®Google Scholar
• Cornelis F, Silk M, Schoder H, et al. Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities. Eur J Nucl Med Mol Imaging. 2014;41(12):2265–2272.
   PubMed Web of Science ®Google Scholar
• Francica G, Meloni MF, Riccardi L, et al. Ablation treatment of primary and secondary liver tumors under contrast-enhanced ultrasound guidance in field practice of interventional ultrasound centers. A multicenter study. Eur J Radiol. 2018;105:96–101.
   PubMed Web of Science ®Google Scholar
• Sotirchos VS, Petrovic LM, Gönen M, et al. Colorectal cancer liver metastases: Biopsy of the ablation zone and margins can be used to predict oncologic outcome. Radiology. 2016;280(3):949–959.
   PubMed Web of Science ®Google Scholar
• Sofocleous CT, Garg S, Petrovic LM, et al. Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies. Ann Surg Oncol. 2012;19(13):4262–4269.
   PubMed Web of Science ®Google Scholar
• Sofocleous CT, Nascimento RG, Petrovic LM, et al. Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. Radiology. 2008;249(1):364–374.
   PubMed Web of Science ®Google Scholar
• Sotirchos VS, Fujisawa S, Vakiani E, et al. Fluorescent tissue assessment of colorectal cancer liver metastases ablation zone: a potential real-time biomarker of complete tumor ablation. Ann Surg Oncol. 2019;26(6):1833–1840.
   PubMed Web of Science ®Google Scholar
• Tanis E, Spliethoff JW, Evers DJ, et al. Real-time in vivo assessment of radiofrequency ablation of human colorectal liver metastases using diffuse reflectance spectroscopy. Eur J Surg Oncol. 2016;42(2):251–259.
   PubMed Web of Science ®Google Scholar
• Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery. 1986;100(2):278–284.
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Palese C, Jarnagin WR, et al. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg. 2000;4(2):178–184.
   PubMed Web of Science ®Google Scholar
• Mise Y, Aloia TA, Brudvik KW, et al. Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival. Annal Surg. 2016;263(1):146–152.
   PubMed Web of Science ®Google Scholar
• Moris D, Dimitroulis D, Vernadakis S, et al. Parenchymal-sparing hepatectomy as the new doctrine in the treatment of liver-metastatic colorectal disease: beyond oncological outcomes. Anticancer Res. 2017;37(1):9–14.
   PubMed Web of Science ®Google Scholar
• Kokudo N, Tada K, Seki M, et al. Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg. 2001;181(2):153–159.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Shimada H, Matsumoto C, et al. Impact of the degree of liver resection on survival for patients with multiple liver metastases from colorectal cancer. World J Surg. 2008;32(9):2057–2069.
   PubMed Web of Science ®Google Scholar
• Mizutani J, Hiraoka T, Yamashita R, et al. Promotion of hepatic metastases by liver resection in the rat. Br J Cancer. 1992;65(6):794–797.
   PubMed Web of Science ®Google Scholar
• Lim C, Cauchy F, Azoulay D, et al. Tumour progression and liver regeneration-insights from animal models. Nat Rev Gastroenterol Hepatol. 2013;10(8):452–462.
   PubMed Web of Science ®Google Scholar
• Chan KM, Wu TH, Cheng CH, et al. Prognostic significance of the number of tumors and aggressive surgical approach in colorectal cancer hepatic metastasis. World J Surg Oncol. 2014;12:155.
   PubMed Web of Science ®Google Scholar
• Park MS, Yi NJ, Son SY, You T, et al. Histopathologic factors affecting tumor recurrence after hepatic resection in colorectal liver metastases. Ann Surg Treat Res. 2014;87(1):14–21.
   PubMed Web of Science ®Google Scholar
• Odisio BC, Yamashita S, Huang SY, et al. Impact of prior hepatectomy history on local tumor progression after percutaneous ablation of colorectal liver metastases. J Vasc Interv Radiol. 2018;29(3):395–403 e1.
   PubMed Web of Science ®Google Scholar
• Brouquet A, Vauthey JN, Badgwell BD, et al. Hepatectomy for recurrent colorectal liver metastases after radiofrequency ablation. Br J Surg. 2011;98(7):1003–1009.
   PubMed Web of Science ®Google Scholar
• Solbiati L, Ahmed M, Cova L, et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology. 2012;265(3):958–968.
   PubMed Web of Science ®Google Scholar
• Schullian P, Johnston EW, Putzer D, et al. Stereotactic radiofrequency ablation (SRFA) for recurrent colorectal liver metastases after hepatic resection. Eur J Surg Oncol. 2021;47(4):866–873.
   Web of Science ®Google Scholar
• Fan XX, Lv SY, Zhang MW, et al. Clinical analysis of ultrasound-guided radiofrequency ablation for recurrent colorectal liver metastases after hepatectomy. World J Surg Oncol. 2020;18(1):76.
   PubMed Web of Science ®Google Scholar
• Ruers T, Van Coevorden F, Punt CJ, et al. Local treatment of unresectable colorectal liver metastases: Results of a randomized phase II trial. J Natl Cancer Inst. 2017;109(9):djx015.
   PubMedGoogle Scholar
• Karanicolas PJ, Jarnagin WR, Gonen M, et al. Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases. JAMA Surg. 2013;148(7):597–601.
   PubMed Web of Science ®Google Scholar
• Hof J, Joosten HJ, Havenga K, et al. Radiofrequency ablation is beneficial in simultaneous treatment of synchronous liver metastases and primary colorectal cancer. PLoS One. 2018;13(3):e0193385.
   PubMed Web of Science ®Google Scholar
• Lee H, Heo JS, Cho YB, et al. Hepatectomy vs radiofrequency ablation for colorectal liver metastasis: a propensity score analysis. WJG. 2015;21(11):3300–3307.
   PubMed Web of Science ®Google Scholar
• Hof J, Wertenbroek MW, Peeters PM, et al. Outcomes after resection and/or radiofrequency ablation for recurrence after treatment of colorectal liver metastases. Br J Surg. 2016;103(8):1055–1062.
   PubMed Web of Science ®Google Scholar
• Vietti Violi N, Duran R, Demartines N, et al. Local recurrence rate in patients with colorectal cancer liver metastasis after wedge resection or percutaneous radiofrequency ablation. Int J Hyperthermia. 2018;34(7):1020–1028.
   PubMed Web of Science ®Google Scholar
• Weng M, Zhang Y, Zhou D, et al. Radiofrequency ablation versus resection for colorectal cancer liver metastases: a meta-analysis. PLoS One. 2012;7(9):e45493.
   PubMed Web of Science ®Google Scholar
• Meijerink MR, Puijk RS, van Tilborg A, et al. Radiofrequency and microwave ablation compared to systemic chemotherapy and to partial hepatectomy in the treatment of colorectal liver metastases: a systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2018;41(8):1189–1204.
   PubMed Web of Science ®Google Scholar
• Tinguely P, Dal G, Bottai M, et al. Microwave ablation versus resection for colorectal cancer liver metastases - A propensity score analysis from a population-based nationwide registry. Eur J Surg Oncol. 2020;46(3):476–485.
   PubMed Web of Science ®Google Scholar
• Puijk RS, Ruarus AH, Vroomen L, COLLISION Trial Group, et al. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer. 2018;18(1):821.
   PubMed Web of Science ®Google Scholar
• Philips P, Groeschl RT, Hanna EM, et al. Single-stage resection and microwave ablation for bilobar colorectal liver metastases. Br J Surg. 2016;103(8):1048–1054.
   PubMed Web of Science ®Google Scholar
• Okuno M, Kawaguchi Y, De Bellis M, et al. A new sequential treatment strategy for multiple colorectal liver metastases: Planned incomplete resection and postoperative completion ablation for intentionally-untreated tumors under guidance of cross-sectional imaging. Eur J Surg Oncol. 2021;47(2):311–316.
   Web of Science ®Google Scholar
• Faitot F, Faron M, Adam R, et al. Two-stage hepatectomy versus 1-stage resection combined with radiofrequency for bilobar colorectal metastases: a case-matched analysis of surgical and oncological outcomes. Ann Surg. 2014;260(5):822–827.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Shimada H, Nagano Y, et al. Outcome after hepatic resection versus combined resection and microwave ablation for multiple bilobar colorectal metastases to the liver. Surgery. 2006;139(2):263–273.
   PubMed Web of Science ®Google Scholar
• Mizuno T, Cloyd JM, Omichi K, et al. Two-stage hepatectomy vs one-stage major hepatectomy with contralateral resection or ablation for advanced bilobar colorectal liver metastases. J Am Coll Surg. 2018;226(5):825–834.
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Kopetz S, Newhook TE, et al. Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases. Clin Cancer Res. 2019;25(19):5843–5851.
   PubMed Web of Science ®Google Scholar
• Datta J, Smith JJ, Chatila WK, McAuliffe JC, et al. Coaltered ras/B-raf and TP53 is associated with extremes of survivorship and distinct patterns of metastasis in patients with metastatic colorectal cancer. Clin Cancer Res. 2020;26(5):1077–1085.
   PubMed Web of Science ®Google Scholar
• Denbo JW, Yamashita S, Passot G, et al. RAS mutation is associated with decreased survival in patients undergoing repeat hepatectomy for colorectal liver metastases. J Gastrointest Surg. 2017;21(1):68–77.
   PubMed Web of Science ®Google Scholar
• Ali MA, Di Sandro S, Lauterio A, et al. Repeat hepatectomy for recurrent colorectal liver metastases: is it worth the challenge? J Gastrointest Surg. 2015;19(12):2192–2198.
   PubMed Web of Science ®Google Scholar
• Wicherts DA, de Haas RJ, Salloum C, et al. Repeat hepatectomy for recurrent colorectal metastases. Br J Surg. 2013;100(6):808–818.
   PubMed Web of Science ®Google Scholar
• Creasy JM, Sadot E, Koerkamp BG, et al. Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? Surgery. 2018;163(6):1238–1244.
   PubMed Web of Science ®Google Scholar
• Urbonas T, Anderson EM, Gordon-Weeks AN, et al. Factors predicting ablation site recurrence following percutaneous microwave ablation of colorectal hepatic metastases. HPB (Oxford). 2019;21(9):1175–1184.
   PubMed Web of Science ®Google Scholar
• Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7):795–801.
   PubMed Web of Science ®Google Scholar
• Germano G, Mauri G, Siravegna G, et al. Parallel evaluation of circulating tumor DNA and circulating tumor cells in metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17(1):80–83.
   PubMed Web of Science ®Google Scholar
• Khan KH, Cunningham D, Werner B, et al. Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discov. 2018;8(10):1270–1285.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–779.
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Miller MC, et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 2010;21(5):1006–1012.
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213–3221.
   PubMed Web of Science ®Google Scholar
• Rozenblum N, Zeira E, Scaiewicz V, et al. Oncogenesis: an "off-Target" effect of radiofrequency ablation. Radiology. 2015;276(2):426–432.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Kumar G, Moussa M, et al. Hepatic radiofrequency ablation-induced stimulation of distant tumor growth is suppressed by c-Met inhibition. Radiology. 2016;279(1):103–117.
   PubMed Web of Science ®Google Scholar
• Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532–536.
   PubMed Web of Science ®Google Scholar
• Diaz LA, Jr., Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537–540.
   PubMed Web of Science ®Google Scholar
• Underwood JJ, Quadri RS, Kalva SP, et al. Liquid biopsy for cancer: review and implications for the radiologist. Radiology. 2020;294(1):5–17.
   PubMed Web of Science ®Google Scholar
• Falcão D, Alexandrino H, Caetano Oliveira R, et al. Histopathologic patterns as markers of prognosis in patients undergoing hepatectomy for colorectal cancer liver metastases - pushing growth as an independent risk factor for decreased survival. Eur J Surg Oncol. 2018;44(8):1212–1219.
   PubMed Web of Science ®Google Scholar
• Galjart B, Nierop PMH, van der Stok EP, et al. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases. Angiogenesis. 2019;22(2):355–368.
   PubMed Web of Science ®Google Scholar
• Nierop PMH, Höppener DJ, van der Stok EP, et al. Histopathological growth patterns and positive margins after resection of colorectal liver metastases. HPB (Oxford). 2020;22(6):911–919.
   PubMed Web of Science ®Google Scholar
• Buisman FE, van der Stok EP, Galjart B, et al. Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases. Clin Exp Metastasis. 2020;37(5):593–605.
   PubMed Web of Science ®Google Scholar
• van Dam PJ, van der Stok EP, Teuwen LA, et al. International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. Br J Cancer. 2017;117(10):1427–1441.
   PubMed Web of Science ®Google Scholar
• Nierop PMH, Galjart B, Höppener DJ, et al. Salvage treatment for recurrences after first resection of colorectal liver metastases: the impact of histopathological growth patterns. Clin Exp Metastasis. 2019;36(2):109–118.
   PubMed Web of Science ®Google Scholar
• Frentzas S, Simoneau E, Bridgeman VL, et al. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat Med. 2016;22(11):1294–1302.
   PubMed Web of Science ®Google Scholar
• Meijerink MR, Ruarus AH, Vroomen L, et al. Irreversible electroporation to treat unresectable colorectal liver metastases (COLDFIRE-2): a phase II, two-center, single-arm clinical trial. Radiology. 2021:203089.
   Google Scholar
• Fan XX, Lv SY, Zhang MW, et al. Clinical analysis of ultrasound-guided radiofrequency ablation for recurrent colorectal liver metastases after hepatectomy. World J Surg Oncol. 2020;18(1):76.
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Pedersoli F, Schulze-Hagen M, et al. Salvage RFA in patients with intrahepatic recurrence after major hepatic surgery for colorectal cancer liver metastases: mid-term outcome. Eur Radiol. 2020;30(2):1221–1227.
   PubMed Web of Science ®Google Scholar
• Cornelis FH, Petre EN, Vakiani E, et al. Immediate postablation (18)F-FDG injection and corresponding SUV are surrogate biomarkers of local tumor progression after thermal ablation of colorectal carcinoma liver metastases. J Nucl Med. 2018;59(9):1360–1365.
   PubMed Web of Science ®Google Scholar
• Schicho A, Niessen C, Haimerl M, et al. Long-term survival after percutaneous irreversible electroporation of inoperable colorectal liver metastases. Cancer Manag Res. 2019;11:317–322.
   PubMed Web of Science ®Google Scholar
• Mao R, Zhao JJ, Bi XY, et al. Resectable recurrent colorectal liver metastasis: can radiofrequency ablation replace repeated metastasectomy? ANZ J Surg. 2019;89(7–8):908–913.
   PubMed Web of Science ®Google Scholar
• van Amerongen MJ, van der Stok EP, Fütterer JJ, et al. Results after simultaneous surgery and RFA liver ablation for patients with colorectal carcinoma and synchronous liver metastases. Eur J Surg Oncol. 2019;45(12):2334–2339.
   PubMed Web of Science ®Google Scholar
• Dupré A, Jones RP, Diaz-Nieto R, et al. Curative-intent treatment of recurrent colorectal liver metastases: a comparison between ablation and resection. Eur J Surg Oncol. 2017;43(10):1901–1907.
   PubMed Web of Science ®Google Scholar
• Imai K, Allard MA, Castro Benitez C, et al. Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases. Br J Surg. 2017;104(5):570–579.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Margonis GA, Andreatos N, et al. Combined resection and RFA in colorectal liver metastases: stratification of long-term outcomes. J Surg Res. 2016;206(1):182–189.
   PubMed Web of Science ®Google Scholar
• Valls C, Ramos E, Leiva D, et al. Safety and efficacy of ultrasound-guided radiofrequency ablation of recurrent colorectal cancer liver metastases after hepatectomy. Scand J Surg. 2015;104(3):169–175.
   PubMed Web of Science ®Google Scholar